RPE65 and retinitis pigmentosa: Scholl et al. (2015) [19] investigated the effects of oral QLT091001 in 18 patients with retinitis pigmentosa (RP) resulting from mutations in the RPE65 or LRAT genes, aged 5 to 65 years.